HK1256595A1 - Method for preparing ophthalmic preparation containing thymosin beta-4 - Google Patents

Method for preparing ophthalmic preparation containing thymosin beta-4 Download PDF

Info

Publication number
HK1256595A1
HK1256595A1 HK18115713.4A HK18115713A HK1256595A1 HK 1256595 A1 HK1256595 A1 HK 1256595A1 HK 18115713 A HK18115713 A HK 18115713A HK 1256595 A1 HK1256595 A1 HK 1256595A1
Authority
HK
Hong Kong
Prior art keywords
thymosin
composition
container
ophthalmic preparation
inert gas
Prior art date
Application number
HK18115713.4A
Other languages
English (en)
Chinese (zh)
Inventor
Si Young Lee
Sin Wook Kang
Ji Hye SUNG
Tae Heum UM
Original Assignee
HLB Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HLB Therapeutics Co., Ltd. filed Critical HLB Therapeutics Co., Ltd.
Publication of HK1256595A1 publication Critical patent/HK1256595A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B23/00—Noble gases; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A61J1/12—Bag-type containers with means for holding samples of contents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HK18115713.4A 2015-10-06 2015-12-18 Method for preparing ophthalmic preparation containing thymosin beta-4 HK1256595A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0140489 2015-10-06
KR20150140489 2015-10-06
PCT/KR2015/013981 WO2017061663A1 (ko) 2015-10-06 2015-12-18 티모신 베타 4를 포함하는 안약의 제조방법

Publications (1)

Publication Number Publication Date
HK1256595A1 true HK1256595A1 (en) 2019-09-27

Family

ID=58487995

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115713.4A HK1256595A1 (en) 2015-10-06 2015-12-18 Method for preparing ophthalmic preparation containing thymosin beta-4

Country Status (7)

Country Link
US (1) US10744088B2 (OSRAM)
EP (1) EP3342398B1 (OSRAM)
JP (2) JP6996713B2 (OSRAM)
KR (1) KR102487614B1 (OSRAM)
ES (1) ES3064258T3 (OSRAM)
HK (1) HK1256595A1 (OSRAM)
WO (1) WO2017061663A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
MX2021004183A (es) * 2018-10-10 2021-10-26 Presbyopia Therapies Inc Composiciones y metodos para el tratamiento de la presbicia.
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN115266995B (zh) * 2022-08-02 2023-10-13 兆科（广州）眼科药物有限公司 一种生发肽制剂中有关物质的分析方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
WO1996031195A1 (en) * 1995-04-04 1996-10-10 Otsuka Pharmaceutical Co., Ltd. Package holding a procaterol hydrochloride aqueous solution formulation, and a procaterol hydrochloride aqueous solution formulation
AU766826B2 (en) 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
CN1188414C (zh) * 1998-10-14 2005-02-09 协和发酵工业株式会社 稳定吡唑并吖啶酮衍生物水溶液的方法
BRPI0513978A (pt) * 2004-07-30 2008-05-20 Otsuka Pharma Co Ltd frasco de comprimir e conta-gotas de uso oftalmológico utilizando o mesmo
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
US8383576B2 (en) * 2005-06-17 2013-02-26 Regenerx Biopharmaceuticals, Inc. LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
WO2008108927A2 (en) * 2007-03-06 2008-09-12 Regenerx Biopharmaceuticals, Inc. Methods and compositions for stabilizing polypeptides
SI3461503T1 (sl) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法

Also Published As

Publication number Publication date
WO2017061663A1 (ko) 2017-04-13
JP2020183391A (ja) 2020-11-12
KR102487614B1 (ko) 2023-01-12
US10744088B2 (en) 2020-08-18
JP6996713B2 (ja) 2022-02-04
KR20170041109A (ko) 2017-04-14
EP3342398A4 (en) 2019-03-20
JP2018531905A (ja) 2018-11-01
US20180228729A1 (en) 2018-08-16
ES3064258T8 (en) 2026-05-13
ES3064258T3 (en) 2026-04-23
EP3342398C0 (en) 2026-02-11
EP3342398A1 (en) 2018-07-04
EP3342398B1 (en) 2026-02-11

Similar Documents

Publication Publication Date Title
EP3342398B1 (en) Method for preparing ophthalmic preparation containing thymosin beta-4
EP2618814B1 (en) Caspofungin composition
CA2191317A1 (en) A pharmaceutical preparation comprising glucagon
IL218504A (en) Use of lkktet and / or lkktnt peptides to treat dry eye syndrome
US20030069183A1 (en) Lyophilized HGF preparations
JPH10212241A (ja) Ｂｄｎｆを安定に含有する製剤
KR20190137788A (ko) 안정한 펩타이드 조성물
CN1315531C (zh) 用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
WO2008108927A2 (en) Methods and compositions for stabilizing polypeptides
RU2555332C2 (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
EP3715451A2 (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
EP3403645A1 (en) Autoclavable suspensions of cyclosporin a form 2
KR101322527B1 (ko) 잔탄 검 및 테르페노이드를 포함하는 점안제
KR101838759B1 (ko) 점안제
EP2711374A1 (en) Novel metalloprotein and process for producing same, and prophylactic or therapeutic agent for corneal and conjunctival diseases comprising said metalloprotein
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
EP3287141A1 (en) Nerve growth factor composition and powder injection
EP2704747B1 (en) Eye drops for treatment of conjunctivochalasis
KR100671449B1 (ko) 송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물
EP4609874A1 (en) Pharmaceutical composition comprising echinocandin analog and preparation method for pharmaceutical composition
US20260115259A1 (en) Ophthalmic pharmaceutical composition and use thereof
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
HK1172820A (en) Eye drops
HK1202078B (en) Autoclavable suspensions of cyclosporin a form 2